Rita Samuel Selected Research

Valsartan Drug Combination Amlodipine

8/2011	Combination angiotensin-receptor blocker (ARB)/calcium channel blocker with HCTZ vs the maximal recommended dose of an ARB with HCTZ in patients with stage 2 hypertension: the exforge as compared to losartan treatment in stage 2 systolic hypertension (EXALT) study.
7/2011	Moderate versus intensive treatment of hypertension using amlodipine/valsartan and with the addition of hydrochlorothiazide for patients uncontrolled on angiotensin receptor blocker monotherapy: results in racial/ethnic subgroups.
4/2011	The role of ambulatory blood pressure monitoring compared with clinic and home blood pressure measures in evaluating moderate versus intensive treatment of hypertension with amlodipine/valsartan for patients uncontrolled on angiotensin receptor blocker monotherapy.
1/2011	Moderate versus intensive treatment of hypertension with amlodipine/valsartan for patients uncontrolled on angiotensin receptor blocker monotherapy.
1/2011	Ambulatory blood pressure response to triple therapy with an angiotensin-receptor blocker (ARB), calcium-channel blocker (CCB), and HCTZ versus dual therapy with an ARB and HCTZ.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Rita Samuel Research Topics

Disease

12	Hypertension (High Blood Pressure) 03/2012 - 06/2008
5	Type 2 Diabetes Mellitus (MODY) 01/2020 - 01/2009
4	Isolated Systolic Hypertension 04/2012 - 08/2011
3	Dyslipidemias (Dyslipidemia) 01/2020 - 01/2018
2	Stroke (Strokes) 01/2009 - 05/2005
1	Cardiovascular Diseases (Cardiovascular Disease) 11/2019
1	Coronary Disease (Coronary Heart Disease) 11/2019
1	Diabetes Complications 11/2019
1	Type 1 Diabetes Mellitus (Autoimmune Diabetes) 12/2017
1	Dizziness (Lightheadedness) 08/2011
1	Essential Hypertension 12/2009
1	Coronary Artery Disease (Coronary Atherosclerosis) 01/2009
1	Heart Failure 01/2009
1	Myocardial Infarction 01/2009
1	Obesity 01/2009
1	Glucose Intolerance 01/2009
1	Metabolic Syndrome (Dysmetabolic Syndrome X) 01/2009
1	Diabetes Mellitus 01/2009
1	Chronic Renal Insufficiency 01/2009
1	Cough 01/2009
1	Venous Thrombosis (Deep-Vein Thrombosis) 05/2005
1	Ischemic Stroke 05/2005
1	Pulmonary Embolism 05/2005
1	Paralysis (Palsy) 05/2005
1	Venous Thromboembolism 05/2005

Drug/Important Bio-Agent (IBA)

11	Valsartan (Vals)FDA Link 04/2012 - 06/2008
9	Hydrochlorothiazide (Esidrix)FDA LinkGeneric 04/2012 - 06/2008
7	Angiotensin Receptor AntagonistsIBA 03/2012 - 06/2008
5	Valsartan Drug Combination Amlodipine FDA Link 08/2011 - 01/2011
4	Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA 01/2020 - 12/2017
4	alirocumabIBA 01/2020 - 12/2017
4	Amlodipine (Norvasc)FDA LinkGeneric 08/2011 - 06/2009
3	Antihypertensive Agents (Antihypertensives)IBA 03/2012 - 01/2011
2	Insulin (Novolin)FDA Link 11/2019 - 12/2017
2	Proprotein Convertase 9IBA 11/2019 - 01/2018
2	Losartan (Cozaar)FDA LinkGeneric 08/2011 - 01/2011
1	Apolipoproteins B (ApoB)IBA 01/2020
1	ApolipoproteinsIBA 01/2020
1	HDL CholesterolIBA 01/2020
1	Triglycerides (Triacylglycerol)IBA 01/2020
1	oxidized low density lipoproteinIBA 11/2019
1	LipidsIBA 01/2018
1	LDL CholesterolIBA 12/2017
1	Renin InhibitorsIBA 03/2012
1	aliskiren FDA Link 03/2012
1	Calcium Channel Blockers (Blockers, Calcium Channel)IBA 08/2011
1	Proteins (Proteins, Gene)FDA Link 01/2009
1	Angiotensin-Converting Enzyme Inhibitors (ACE Inhibitors)IBA 01/2009
1	AlbuminsIBA 01/2009
1	Peptidyl-Dipeptidase A (Angiotensin Converting Enzyme)IBA 01/2009
1	DiureticsIBA 06/2008
1	Enoxaparin (Lovenox)FDA LinkGeneric 05/2005
1	Low-Molecular-Weight Heparin (Heparin, Low Molecular Weight)IBA 05/2005
1	Heparin (Liquaemin)FDA LinkGeneric 05/2005

Therapy/Procedure

8	Therapeutics 11/2019 - 12/2009
1	Aftercare (After-Treatment) 05/2005